Pharmacological Tolerance in the Treatment of Fragile X Syndrome

Pharmacological Tolerance in the Treatment of Fragile X Syndrome

With a $90,000 grant from FRAXA Research Foundation, Dr. Patrick McCamphill and Dr. Mark Bear at Massachusetts Institute of Technology (MIT) will further investigate drug tolerance and ways to overcome it. 

Read more

An Experimental Drug’s Bitter End – NYTimes.com

By ANDREW POLLACK Holly Usrey-Roos will never forget when her son, Parker, then 10, accidentally broke a drinking glass and said, “I’m sorry, Mom. I love you.” Ms. Usrey-Roos with her son, Parker. The experimental drug he took for years, she said, “opened the lid and let Parker out.” Now, however, the drug is being taken away. The situation raises questions about what, if anything, drug companies owe to patients participating in their clinical trials. It also points out the difficulties in developing drugs to treat autism and fragile X syndrome. If the drug worked so well in some patients, why has it not succeeded so far in clinical trials? Read the article:  An Experimental Drug’s Bitter End – NYTimes.com.

Read more